TORONTO, Jan. 8 /CNW/ - SQI Diagnostics Inc. (TSX-Venture: SQD), a
medical systems automation company focused on evolving laboratory-based
biomarker testing, today announced that it has shipped the first SQiDworks(TM)
platform and accompanying QuantiSpot(TM) microarray consumables to Mount Sinai
Hospital, which operates a globally recognized autoimmune reference laboratory
in Toronto. Mount Sinai will begin validation trials evaluating the analytic
performance of the SQiDworks/QuantiSpot system in diagnosing rheumatoid
arthritis using its panel of commonly assayed biomarkers.
